M&R Capital Management Inc. cut its position in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 1.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 19,680 shares of the company’s stock after selling 200 shares during the quarter. M&R Capital Management Inc.’s holdings in Henry Schein were worth $1,156,000 at the end of the most recent quarter.
A number of other hedge funds have also recently bought and sold shares of the business. Bank of New York Mellon Corp increased its holdings in shares of Henry Schein by 4.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 2,453,681 shares of the company’s stock valued at $143,271,000 after purchasing an additional 95,537 shares during the period. Geode Capital Management LLC increased its holdings in shares of Henry Schein by 2.2% in the 1st quarter. Geode Capital Management LLC now owns 2,387,304 shares of the company’s stock valued at $120,383,000 after purchasing an additional 51,836 shares during the period. Alliancebernstein L.P. increased its holdings in Henry Schein by 0.3% in the first quarter. Alliancebernstein L.P. now owns 2,233,623 shares of the company’s stock worth $112,843,000 after buying an additional 7,128 shares during the last quarter. Sound Shore Management Inc CT boosted its position in shares of Henry Schein by 32.2% during the second quarter. Sound Shore Management Inc CT now owns 1,437,167 shares of the company’s stock worth $83,916,000 after buying an additional 350,379 shares during the period. Finally, Goldman Sachs Group Inc. boosted its position in Henry Schein by 6.4% during the second quarter. Goldman Sachs Group Inc. now owns 1,276,316 shares of the company’s stock valued at $74,524,000 after purchasing an additional 76,665 shares during the last quarter. 99.97% of the stock is owned by institutional investors.
Several analysts have issued reports on HSIC shares. BidaskClub lowered Henry Schein from a “hold” rating to a “sell” rating in a research note on Friday, September 25th. ValuEngine lowered Henry Schein from a “hold” rating to a “sell” rating in a research note on Friday, August 7th. Zacks Investment Research raised Henry Schein from a “sell” rating to a “hold” rating and set a $71.00 target price on the stock in a report on Monday, July 20th. Finally, TheStreet cut Henry Schein from a “b” rating to a “c+” rating in a report on Tuesday, August 4th. Five analysts have rated the stock with a sell rating, eight have issued a hold rating and three have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $64.33.
In other Henry Schein news, EVP Gerald A. Benjamin sold 14,430 shares of the business’s stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $68.08, for a total value of $982,394.40. Following the completion of the transaction, the executive vice president now owns 114,189 shares of the company’s stock, valued at approximately $7,773,987.12. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 1.05% of the company’s stock.
About Henry Schein
Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Read More: Quiet Period Expirations Explained
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.